Jiansong Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jiansong Cheng has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- Peng George Wang
Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China
6 shared publications Pei Liu
State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials (Ministry of Education), Frontiers Science Center for Cell Responses, College of Life Sciences, Nankai University, Tianjin 300071, China
5 shared publications- Qiang Zhao
State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials (Ministry of Education), Frontiers Science Center for Cell Responses, College of Life Sciences, Nankai University, Tianjin 300071, China
4 shared publications Weiqing Han
Nankai University
4 shared publicationsYangyang Xu
College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin, 300353, PR China
4 shared publicationsFaxing Wang
State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, P. R. China
3 shared publications
Latest Publications
- Open Access
- 19 September 2025
- Published by Scilight Press Pty Ltd in Regenerative Medicine and Dentistry
- Vol. 2  (3) , 13
Controlled Codelivery of Hydrogen Sulfide and Nitric Oxide for the Treatment of Full-Thickness Skin Wound
Chronic wounds present significant clinical challenges stemming from persistent inflammation, impaired angiogenesis, and disrupted tissue homeostasis. Nitric oxide (NO) and hydrogen sulfide (H2S) are important gaseous signalling molecules that play critical regulatory roles in the pathophysiology of numerous diseases. In the present study, we designed a novel prodrug, TSNO, which releases H2S and NO in a controlled manner under the catalysis of GSH and the engineered enzyme A4-β-GalH363A. Furthermore, a functional wound dressing was prepared by incorporating TSNO into an electrospun poly(ε-caprolactone) (PCL) mat, and the therapeutic efficacy was evaluated in a full-thickness skin wound model established in mice. Results showed that the functional wound dressing effectively accelerated the wound healing process by enhancing collagen synthesis, promoting angiogenesis, and regulating inflammation via controlled codelivery of H2S and NO. Taken together, the functional wound dressing developed in this study represents a promising candidate for treating large-scale skin wounds in the clinic.
- 19 September 2025
- Published by Scilight Press Pty Ltd in Regenerative Medicine and Dentistry
- Vol. 2  (3) , 13
Open AccessControlled Codelivery of Hydrogen Sulfide and Nitric Oxide for the Treatment of Full-Thickness Skin Wound
Chronic wounds present significant clinical challenges stemming from persistent inflammation, impaired angiogenesis, and disrupted tissue homeostasis. Nitric oxide (NO) and hydrogen sulfide (H2S) are important gaseous signalling molecules that play critical regulatory roles in the pathophysiology of numerous diseases. In the present study, we designed a novel prodrug, TSNO, which releases H2S and NO in a controlled manner under the catalysis of GSH and the engineered enzyme A4-β-GalH363A. Furthermore, a functional wound dressing was prepared by incorporating TSNO into an electrospun poly(ε-caprolactone) (PCL) mat, and the therapeutic efficacy was evaluated in a full-thickness skin wound model established in mice. Results showed that the functional wound dressing effectively accelerated the wound healing process by enhancing collagen synthesis, promoting angiogenesis, and regulating inflammation via controlled codelivery of H2S and NO. Taken together, the functional wound dressing developed in this study represents a promising candidate for treating large-scale skin wounds in the clinic.
- Open Access
- 1 December 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9  (48) , eadi9967
Intracellular delivery of nitric oxide enhances the therapeutic efficacy of mesenchymal stem cells for myocardial infarction
Cell therapy by autologous mesenchymal stem cells (MSCs) is a clinically acceptable strategy for treating various diseases. Unfortunately, the therapeutic efficacy is largely affected by the low quality of MSCs collected from patients. Here, we showed that the gene expression of MSCs from patients with diabetes was differentially regulated compared to that of MSCs from healthy controls. Then, MSCs were genetically engineered to catalyze an NO prodrug to release NO intracellularly. Compared to extracellular NO conversion, intracellular NO delivery effectively prolonged survival and enhanced the paracrine function of MSCs, as demonstrated by in vitro and in vivo assays. The enhanced therapeutic efficacy of engineered MSCs combined with intracellular NO delivery was further confirmed in mouse and rat models of myocardial infarction, and a clinically relevant cell administration paradigm through secondary thoracotomy has been attempted.
- 1 December 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9  (48) , eadi9967
Open AccessIntracellular delivery of nitric oxide enhances the therapeutic efficacy of mesenchymal stem cells for myocardial infarction
Cell therapy by autologous mesenchymal stem cells (MSCs) is a clinically acceptable strategy for treating various diseases. Unfortunately, the therapeutic efficacy is largely affected by the low quality of MSCs collected from patients. Here, we showed that the gene expression of MSCs from patients with diabetes was differentially regulated compared to that of MSCs from healthy controls. Then, MSCs were genetically engineered to catalyze an NO prodrug to release NO intracellularly. Compared to extracellular NO conversion, intracellular NO delivery effectively prolonged survival and enhanced the paracrine function of MSCs, as demonstrated by in vitro and in vivo assays. The enhanced therapeutic efficacy of engineered MSCs combined with intracellular NO delivery was further confirmed in mouse and rat models of myocardial infarction, and a clinically relevant cell administration paradigm through secondary thoracotomy has been attempted.
- Open Access
- 3 May 2023
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 8  (7) , 843-861
Endothelium-Mimetic Surface Modification Improves Antithrombogenicity and Enhances Patency of Vascular Grafts in Rats and Pigs
- 3 May 2023
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 8  (7) , 843-861
Open AccessEndothelium-Mimetic Surface Modification Improves Antithrombogenicity and Enhances Patency of Vascular Grafts in Rats and Pigs
- Open Access
- 29 April 2023
- Published by Wiley
Calcium iodide mediated coupling of complex fluorooligosaccharides to phenolic peptide
Besides serving as therapeutic agents and building blocks for glycoprotein synthesis, homogeneous synthetic glycopeptides also benefit understanding function of specific glycoform. However, the selectivity coupling of oligosaccharides to a given peptide remains challenging despite the fact that the synthesis of structure-defined complex oligosaccharides has been greatly facilitated by chemoenzymatic based approaches. Herein, a Ca 2+ -promoted glycosylation approach was developed to exclusively modify phenolic peptide using a panel of biologically important glycans.
- 29 April 2023
- Published by Wiley
Open AccessCalcium iodide mediated coupling of complex fluorooligosaccharides to phenolic peptide
Besides serving as therapeutic agents and building blocks for glycoprotein synthesis, homogeneous synthetic glycopeptides also benefit understanding function of specific glycoform. However, the selectivity coupling of oligosaccharides to a given peptide remains challenging despite the fact that the synthesis of structure-defined complex oligosaccharides has been greatly facilitated by chemoenzymatic based approaches. Herein, a Ca 2+ -promoted glycosylation approach was developed to exclusively modify phenolic peptide using a panel of biologically important glycans.
- 25 November 2021
- Published by Pleiades Publishing Ltd in Applied Biochemistry and Microbiology
- Vol. 57  (6) , 719-724
Effect of Gln469 on the Activity and Substrate Specificity of the N-glycosyltransferase from Actinobacillus pleuropneumoniae
N-Glycosyltransferase from Actinobacillus pleuropneumoniae (ApNGT) belongs to a novel class of N-glycosylation-catalyzing enzymes and has been extensively studied in decade. The enzyme transfers UDP-Glc/Gal to the asparagine side chains of the receptor proteins/peptides bearing Asn-Xaa-Ser/Thr (where Xaa ≠Pro) sequons. Recently, the residue of Gln469 located on a unique loop within the active site has been demonstrated to contribute to the stringent selectivity of ApNGT. The relaxed acceptor specificity has been achieved by replacing Gln469 with small residue (such as Ala). To obtain more flexible N-glycosylation biocatalysts for use in glycoengineering applications and also in-depth understanding of the role of Gln469 in catalysis and substrate binding, a set of mutants with deletions of Gln469 and/or its neighboring residues were herein constructed by overlap extension PCR. The activity and specificity of ApNGT were systematically investigated by screening 3 panels of synthetic peptide substrates. Collectively, the results indicated that Gln469 may engage in amino acid residue selectivity and is not requisite for catalysis. Meanwhile, the Δ469 mutant reveals relaxed N-glycosylation site selection and is capable of efficiently glycosylating peptide with positive charged Lys/Arg at +1 position that, however, is disfavored by the wild type ApNGT and other known microbial N-glycosyltransferases.
- 25 November 2021
- Published by Pleiades Publishing Ltd in Applied Biochemistry and Microbiology
- Vol. 57  (6) , 719-724
Effect of Gln469 on the Activity and Substrate Specificity of the N-glycosyltransferase from Actinobacillus pleuropneumoniae
N-Glycosyltransferase from Actinobacillus pleuropneumoniae (ApNGT) belongs to a novel class of N-glycosylation-catalyzing enzymes and has been extensively studied in decade. The enzyme transfers UDP-Glc/Gal to the asparagine side chains of the receptor proteins/peptides bearing Asn-Xaa-Ser/Thr (where Xaa ≠Pro) sequons. Recently, the residue of Gln469 located on a unique loop within the active site has been demonstrated to contribute to the stringent selectivity of ApNGT. The relaxed acceptor specificity has been achieved by replacing Gln469 with small residue (such as Ala). To obtain more flexible N-glycosylation biocatalysts for use in glycoengineering applications and also in-depth understanding of the role of Gln469 in catalysis and substrate binding, a set of mutants with deletions of Gln469 and/or its neighboring residues were herein constructed by overlap extension PCR. The activity and specificity of ApNGT were systematically investigated by screening 3 panels of synthetic peptide substrates. Collectively, the results indicated that Gln469 may engage in amino acid residue selectivity and is not requisite for catalysis. Meanwhile, the Δ469 mutant reveals relaxed N-glycosylation site selection and is capable of efficiently glycosylating peptide with positive charged Lys/Arg at +1 position that, however, is disfavored by the wild type ApNGT and other known microbial N-glycosyltransferases.
- 7 March 2019
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 141  (11) , 4547-4552
Redox-Controlled Site-Specific α2–6-Sialylation
The first bacterial α2–6-sialyltransferase cloned from Photobacterium damselae (Pd2,6ST) has been widely applied for the synthesis of various α2–6-linked sialosides. However, the extreme substrate flexibility of Pd2,6ST makes it unsuitable for site-specific α2–6-sialylation of complex substrates containing multiple galactose and/or N-acetylgalactosamine units. To tackle this problem, a general redox-controlled site-specific sialylation strategy using Pd2,6ST is described. This approach features site-specific enzymatic oxidation of galactose units to mask the unwanted sialylation sites and precisely controlling the site-specific α2–6-sialylation at intact galactose or N-acetylgalactosamine units.
- 7 March 2019
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 141  (11) , 4547-4552
Redox-Controlled Site-Specific α2–6-Sialylation
The first bacterial α2–6-sialyltransferase cloned from Photobacterium damselae (Pd2,6ST) has been widely applied for the synthesis of various α2–6-linked sialosides. However, the extreme substrate flexibility of Pd2,6ST makes it unsuitable for site-specific α2–6-sialylation of complex substrates containing multiple galactose and/or N-acetylgalactosamine units. To tackle this problem, a general redox-controlled site-specific sialylation strategy using Pd2,6ST is described. This approach features site-specific enzymatic oxidation of galactose units to mask the unwanted sialylation sites and precisely controlling the site-specific α2–6-sialylation at intact galactose or N-acetylgalactosamine units.
- 1 January 2019
- Published by Elsevier in Carbohydrate Research
- Vol. 472, 72-75
N-acetyltransferases from three different organisms displaying distinct selectivity toward hexosamines and N-terminal amine of peptides
- 1 January 2019
- Published by Elsevier in Carbohydrate Research
- Vol. 472, 72-75
N-acetyltransferases from three different organisms displaying distinct selectivity toward hexosamines and N-terminal amine of peptides
- 31 December 2018
- Published by Springer Nature in Nature Chemical Biology
- Vol. 15  (2) , 151-160
Targeted delivery of nitric oxide via a ‘bump-and-hole’-based enzyme–prodrug pair
The spatiotemporal generation of nitric oxide (NO), a versatile endogenous messenger, is precisely controlled. Despite its therapeutic potential for a wide range of diseases, NO-based therapies are limited clinically due to a lack of effective strategies for precisely delivering NO to a specific site. In the present study, we developed a novel NO delivery system via modification of an enzyme-prodrug pair of galactosidase-galactosyl-NONOate using a 'bump-and-hole' strategy. Precise delivery to targeted tissues was clearly demonstrated by an in vivo near-infrared imaging assay. The therapeutic potential was evaluated in both rat hindlimb ischemia and mouse acute kidney injury models. Targeted delivery of NO clearly enhanced its therapeutic efficacy in tissue repair and function recovery and abolished side effects due to the systemic release of NO. The developed protocol holds broad applicability in the targeted delivery of important gaseous signaling molecules and offers a potent tool for the investigation of relevant molecular mechanisms.
- 31 December 2018
- Published by Springer Nature in Nature Chemical Biology
- Vol. 15  (2) , 151-160
Targeted delivery of nitric oxide via a ‘bump-and-hole’-based enzyme–prodrug pair
The spatiotemporal generation of nitric oxide (NO), a versatile endogenous messenger, is precisely controlled. Despite its therapeutic potential for a wide range of diseases, NO-based therapies are limited clinically due to a lack of effective strategies for precisely delivering NO to a specific site. In the present study, we developed a novel NO delivery system via modification of an enzyme-prodrug pair of galactosidase-galactosyl-NONOate using a 'bump-and-hole' strategy. Precise delivery to targeted tissues was clearly demonstrated by an in vivo near-infrared imaging assay. The therapeutic potential was evaluated in both rat hindlimb ischemia and mouse acute kidney injury models. Targeted delivery of NO clearly enhanced its therapeutic efficacy in tissue repair and function recovery and abolished side effects due to the systemic release of NO. The developed protocol holds broad applicability in the targeted delivery of important gaseous signaling molecules and offers a potent tool for the investigation of relevant molecular mechanisms.
- 5 July 2018
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 8  (8) , 7222-7227
Successfully Engineering a Bacterial Sialyltransferase for Regioselective α2,6-sialylation
- 5 July 2018
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 8  (8) , 7222-7227
Successfully Engineering a Bacterial Sialyltransferase for Regioselective α2,6-sialylation
- 17 July 2017
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 53  (65) , 9075-9077
A novel enzymatic method for synthesis of glycopeptides carrying natural eukaryotic N-glycans
A novel enzymatic approach was developed for facile production of glycopeptides carrying natural eukaryotic N-glycans. In this approach, peptides can be GlcNAcylated at one or two natural N-glycosylation sites via two-step enzymatic reactions catalyzed by an evolved N-glycosyltransferase (ApNGTQ469A) and a glucosamine N-acetyltransferase (GlmA), respectively. The resulting GlcNAc-peptides were further modified by an endo-β-N-acetylglucosaminidase M mutant (EndoMN175Q) to generate glycopeptides. In three steps of enzymatic catalysis, glycopeptides carrying complex-type N-glycans can be efficiently synthesized.
- 17 July 2017
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 53  (65) , 9075-9077
A novel enzymatic method for synthesis of glycopeptides carrying natural eukaryotic N-glycans
A novel enzymatic approach was developed for facile production of glycopeptides carrying natural eukaryotic N-glycans. In this approach, peptides can be GlcNAcylated at one or two natural N-glycosylation sites via two-step enzymatic reactions catalyzed by an evolved N-glycosyltransferase (ApNGTQ469A) and a glucosamine N-acetyltransferase (GlmA), respectively. The resulting GlcNAc-peptides were further modified by an endo-β-N-acetylglucosaminidase M mutant (EndoMN175Q) to generate glycopeptides. In three steps of enzymatic catalysis, glycopeptides carrying complex-type N-glycans can be efficiently synthesized.